Orthofix Medical/$OFIX
1D1W1MYTD1Y5YMAX
Capital at risk
About Orthofix Medical
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
- Ticker
- $OFIX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,605
- Headquarters
- Lewisville, United States
- Website
- orthofix.com
Orthofix Medical Metrics
BasicAdvanced
$365M
-
-$1.53
0.67
-
Price and volume
Market cap
$365M
Beta
0.67
52-week high
$16.99
52-week low
$8.50
Average daily volume
322K
Financial strength
Current ratio
2.841
Quick ratio
1.526
Long term debt to equity
0.603
Total debt to equity
0.61
Interest coverage (TTM)
-1.81%
Profitability
EBITDA (TTM)
20.928
Gross margin (TTM)
71.26%
Net profit margin (TTM)
-7.41%
Operating margin (TTM)
-4.51%
Effective tax rate (TTM)
-2.39%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
-2.75%
Return on equity (TTM)
-13.91%
Valuation
Price to revenue (TTM)
0.433
Price to book
0.85
Price to tangible book (TTM)
2.17
Price to free cash flow (TTM)
-12.957
Free cash flow yield (TTM)
-7.72%
Free cash flow per share (TTM)
-0.691
Growth
Revenue change (TTM)
2.99%
Earnings per share change (TTM)
-51.82%
3-year revenue growth (CAGR)
11.66%
10-year revenue growth (CAGR)
7.39%
3-year earnings per share growth (CAGR)
-28.49%
10-year earnings per share growth (CAGR)
33.31%
What the Analysts think about Orthofix Medical
Analyst ratings (Buy, Hold, Sell) for Orthofix Medical stock.
Analyst projections of the future price of Orthofix Medical stock.
Bulls say / Bears say
Orthofix reported second quarter net sales of $210.9 million, a 5% pro forma constant-currency increase driven by double-digit growth in its Global Spine and Global Limb Reconstruction segments. (Business Wire)
The restoration of Medicare reimbursement for non-invasive bone growth stimulators removed a meaningful headwind for its Therapeutic Solutions business, underpinning 3% year-over-year growth in the segment. (Business Wire)
Orthofix raised its full-year 2026 net sales guidance to $845 million–$855 million and its adjusted EBITDA guidance to $95 million–$98 million, signaling management’s confidence in sustained growth and margin expansion. (Business Wire)
Despite operational progress, Orthofix recorded a GAAP net loss of $15.8 million (-$0.39 per share) in Q2 2026, underscoring ongoing unprofitable operations. (Business Wire)
Cash, cash equivalents, and restricted cash declined to $104.4 million at June 30 2026 from $120.9 million at March 31 2026, reflecting arbitration and settlement payments tied to legal claims and exerting liquidity pressure. (Business Wire)
Orthofix’s April 9, 2026 realignment eliminated the President, Global Spine Solutions role and saw the departure of the Global Spine president effective June 12 2026, highlighting potential management instability in a core revenue segment. (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2026.
Orthofix Medical Financial Performance
Revenues and expenses
Orthofix Medical Earnings Performance
Company profitability
Upcoming events
No upcoming events
Orthofix Medical News
AllArticlesVideos
Funds containing Orthofix Medical
AllEURGBP
Fund name | Fund size | $OFIX weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Xtrackers S&P 500 Swap£XSPX | £3.1B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.